What is Chardan Capital’s Forecast for CRGX FY2025 Earnings?

CARGO Therapeutics, Inc. (NASDAQ:CRGX) – Research analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for CARGO Therapeutics in a note issued to investors on Monday, March 24th. Chardan Capital analyst G. Livshits expects that the company will earn ($3.59) per share for the year. Chardan Capital currently has a “Neutral” rating on the stock. The consensus estimate for CARGO Therapeutics’ current full-year earnings is ($3.69) per share. Chardan Capital also issued estimates for CARGO Therapeutics’ FY2026 earnings at ($3.58) EPS.

Other analysts have also recently issued reports about the company. Truist Financial cut CARGO Therapeutics from a “buy” rating to a “hold” rating and lowered their price target for the company from $32.00 to $7.00 in a research report on Thursday, January 30th. William Blair lowered shares of CARGO Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, January 30th. JPMorgan Chase & Co. downgraded shares of CARGO Therapeutics from an “overweight” rating to an “underweight” rating in a report on Thursday, January 30th. Jefferies Financial Group cut shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $32.00 to $3.00 in a research note on Thursday, January 30th. Finally, HC Wainwright cut shares of CARGO Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, January 30th. One analyst has rated the stock with a sell rating and six have given a hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $15.00.

CARGO Therapeutics Stock Performance

Shares of CRGX stock opened at $4.18 on Thursday. The firm has a fifty day moving average of $5.35 and a 200-day moving average of $13.59. The stock has a market cap of $192.50 million, a price-to-earnings ratio of -0.98 and a beta of 1.65. CARGO Therapeutics has a 52-week low of $3.00 and a 52-week high of $25.45.

Institutional Trading of CARGO Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Brooklyn Investment Group bought a new position in shares of CARGO Therapeutics during the fourth quarter worth about $27,000. Tower Research Capital LLC TRC grew its stake in shares of CARGO Therapeutics by 565.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,800 shares of the company’s stock worth $84,000 after acquiring an additional 4,929 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of CARGO Therapeutics in the fourth quarter valued at approximately $141,000. Invesco Ltd. bought a new stake in shares of CARGO Therapeutics in the fourth quarter worth $165,000. Finally, ProShare Advisors LLC acquired a new position in CARGO Therapeutics during the fourth quarter worth $171,000. 93.16% of the stock is currently owned by institutional investors and hedge funds.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.